Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 1 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Pike Therapeutics Inc. has 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These matters are assigned to 2 distinct examiners but are concentrated within 1 distinct art unit. The busiest examiner, KUCKLA, ANNA GRACE, is currently overseeing 1 busiest examiner pending action.
The fact that both of the 2 pending office actions are in 1 distinct art unit suggests a very specific technical focus for the company's current pharmaceutical research. Although there are 2 distinct examiners, they are likely working within the same institutional framework of a single art unit. This means the company must manage two different examiner personalities while adhering to the specific guidelines of one technical division. With 2 distinct examiners involved, the company can compare different examination styles within the same art unit. This concentration in 1 distinct art unit simplifies the technical arguments required across these pending matters, even as the company navigates the individual preferences of KUCKLA, ANNA GRACE.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 2 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| KUCKLA, ANNA GRACE | 1 | 53.2% | +54.1% |
| CHANG, KYUNG SOOK | 1 | 60.4% | +40.9% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18929710 | Pharmaceutical Composition and Method for Treating Seizure Disorders | KUCKLA, ANNA GRACE | — |
| 18224183 | Continuous Drug Delivery Systems and Methods | CHANG, KYUNG SOOK | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18929710 | Pharmaceutical Composition and Method for Treating Seizure Disorders | KUCKLA, ANNA GRACE | — |
| 18224183 | Continuous Drug Delivery Systems and Methods | CHANG, KYUNG SOOK | — |
| Art Unit | Apps |
|---|---|
| 1613 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18929710 | Pharmaceutical Composition and Method for Treating Seizure Disorders | KUCKLA, ANNA GRACE | — | §103§112 | Non-Final OA | — | Pending | Oct 29, 2024 |
| 18224183 | Continuous Drug Delivery Systems and Methods | CHANG, KYUNG SOOK | 1613 | §103§112 | Non-Final OA | — | Pending | Jul 20, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial